Page 40 - Quest Diagnostics News Today

Quest Diagnostics (NYSE:DGX – Get Free Report) had its target price boosted by investment analysts at Citigroup from $135.00 to $145.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Citigroup’s target price suggests a potential upside of 5.27% from the company’s previous […]

Quest Diagnostics (NYSE:DGX – Get Free Report) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $8.72-$8.97 for the period, compared to the consensus earnings per share estimate of $8.75. The company issued revenue guidance of $9.40-$9.48 billion, compared to the consensus revenue estimate of […]

The City of Doral will be cutting a ribbon on April 25, 2024, to officially launch a new partnership with Freebee to bring an innovative pilot program to the City.

Quest Diagnostics (NYSE:DGX – Get Free Report) announced its quarterly earnings data on Tuesday. The medical research company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.18, Briefing.com reports. Quest Diagnostics had a net margin of 9.23% and a return on equity of 15.79%. The firm had revenue […]

Quest Diagnostics (NYSE:DGX – Get Free Report) had its target price hoisted by research analysts at Citigroup from $135.00 to $145.00 in a report released on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. Citigroup’s price target suggests a potential upside of 5.27% from the company’s current […]

Plus 19 other New Jersey companies among the best in the U.S.

A look at the day ahead in U.S. and global markets from Mike Dolan World markets have cheered up a bit this week, but ailing Teslas tanking stock price faces a critical earnings test...

First quarter revenues of $2.37 billion, up 1.5% from 2023First quarter reported diluted earnings per share of $1.72, down 3.4% from 2023; and adjusted diluted EPS of $2.04, flat with 2023Full year...

Quest Diagnostics Inc. expanded its Alzheimer’s disease (AD) portfolio with a blood-based biomarker test for phosphorylated tau 217 (pTau217). The test joins the company’s plasma tests for p-tau181, beta-amyloid 42/40 ratio and ApoE genetic risk as well as several cerebrospinal fluid tests for Alzheimer’s.